A phase II study of TAS102 for advanced/recurrent esophageal cancer resistant/intolerable to 5-FU, Platinum compounds, and Taxane
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ECTAS
- 21 Jun 2017 Status changed from active, no longer recruiting to completed.
- 31 May 2016 Status changed from recruiting to active, no longer recruiting.
- 06 Nov 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.